Resumen El producto biosimilar Remicade® de EPIRUS recibe las aprobaciones definitivas en India

. http://cardiobloodreview.wordpress.com Diflucan (Fluconazole) without Rx BOSTON--(BUSINESS WIRE)--EPIRUS Biopharmaceuticals, Inc. Detrol (Tolterodine) (EPIRUS, NASDAQ:EPRS), una compa~n ia biofarmac eutica con sede en Boston centrada en la comercializaci on y desarrollo mundial de anticuerpos monclonales biosimilares, ha anunciado hoy que ha recibido las aprobaciones definitivas de fabricaci on y comercializaci on de su producto biosimilar Remicade® (infliximab), BOW015, del Drug Controller General of India (DCGI). Buy Desal with free Rx BOW015 es el primer biosimilar de infliximab aprobado en India. “Con estas autorizaciones definitivas, ya podemos ofrecer un producto de alta calidad a los pacientes que no se pueden permitir las actuales opciones de tratamiento”, comenta Amit Munshi, presidente y CEO de EPIRUS. El comunicado en el idioma original, es la versi on oficial y autorizada del mismo. Buy Snacks online Buy Diamox (Acetazolamide) with no prescription La traducci on es solamente un medio de ayuda y deber a ser comparada con el texto en idioma original, que es la unica versi on del texto que tendr a validez legal.

Arizona State University Scientist Roy Curtiss Garners AZBio’s Pioneer Award

CHANDLER, Ariz.--(BUSINESS WIRE)--Roy Curtiss, III, Ph.D., of the Biodesign Institute at Arizona State University, has been selected as the recipient of the 2014 AZBio Pioneer Award for Lifetime Achievement by the Arizona BioIndustry Association. “During his career, Roy Curtiss has had a profound impact on microbiology research and been a true pioneer in developing salmonella-based vaccines that are effective against a range of infectious diseases, which are still the leading cause of worldwide death,” said Joan Koerber-Walker, president and CEO of AZBio. “His contributions since being recruited to Arizona a decade ago have continued unabated, and he is now on the cusp of bringing his remarkable discoveries to the marketplace.” “Roy’s lifelong dedication and achievements in bioscience research, education and innovation are really quite remarkable, and his efforts have inspired countless life science careers,” said Biodesign Institute Executive Director Raymond DuBois, M.D., Ph.D. “His passion and commitment in taking on the challenges of combating infectious diseases and the impact he is having on urgent societal problems make him a stellar example of the translational research spirit of the Biodesign Institute.” Curtiss was drawn to ASU President Michael Crow’s vision of a New American University and a new state-of-the-art research enterprise, the Biodesign Institute, which opened in 2004. Ciloxan (Ciprofloxacin) with no prescription Shortly after arriving at ASU, Curtiss received the largest support of his career, more than $15.4 million from the Grand Challenges in Global Health initiative, funded by the Bill and Melinda Gates Foundation. Buy Cipro (Ciprofloxacin) with no prescription He has also received generous and continued support from the National Institutes of Health throughout his career. Curtiss’ primary focus is alleviating worldwide suffering and death from infectious diseases, particularly in the developing world. Buy Cialis Professional (Tadalafil) without prescription At Biodesign, he directs the Center for Infectious Diseases and Vaccinology, where he oversees a 130-member research team working on more than a dozen projects. Ddavp with no Rx He is also a professor in ASU’s School of Life Sciences and a member of the prestigious National Academy of Sciences. One of his major projects is development of a next-generation vaccine against bacterial pneumonia. Buy Runner's Supplements online Bacterial pneumonia kills more children around the world each year than any other infectious disease, and the rising costs of vaccines has spurred researchers to develop new solutions. http://cardiobloodreview.wordpress.com Curtiss and his global team are trying to perfect a safe, yet potent vaccine to fight pneumonia and can be tolerated even by newborn babies — and orally administered as a single-dose, low-cost solution. If successful, the new vaccine against bacterial pneumonia promises to outperform existing injectable vaccine in terms of safety, affordability, ease of distribution and effectiveness. Preliminary studies have been successful, and the vaccine technology has moved forward to human clinical trials. In addition, his team is also targeting vaccine development for a host of other diseases, and to protect poultry and livestock against a broad range of bacterial marauders. Before coming to ASU in 2004, Curtiss was the George William and Irene Keochig Freiberg professor of biology at Washington University in St. Louis, where he chaired the Department of Biology for ten years. His body of published work includes more than 250 reviewed articles. He earned a bachelor’s degree from Cornell University and a doctorate from the University of Chicago. A ceremony honoring Curtiss will take place at the AZBio Awards on September 17, 2014 at the Phoenix Convention Center. The AZBio Awards ceremony celebrates Arizona’s leading educators, innovators and companies. Each year, AZBio honors bioindustry leaders from across the state of Arizona who are illustrative of the depth, breadth and expertise of our bioscience industry. Past recipients of the AZBio Pioneer Award for Lifetime Achievement include: David S. Alberts, M.D., Director Emeritus at the Arizona Cancer Center, Raymond L. Woosley, M.D., Ph.D., Chairman Emeritus of the Critical Path Institute, and Thomas M. Grogan, M.D., founder of Ventana Medical Systems, Inc. For registration and more information, go to .azbio.awards.com. Roy Curtiss III is a member of the National Academy of Sciences fellow of the American Academy of Microbiology; the American Association for the Advancement of Science; the St. Louis Academy of Sciences; and the Arizona Arts, Science and Technology Academy. About AZBio AZBio – The Arizona Bioindustry Association – is comprised of member organizations in business, research, government, and other professions involved in the biosciences. AZBio supports the members of the Arizona bioscience community by providing access to the key resources, connections, and information that support their ability to Connect, Collaborate, Innovate and Succeed thus supporting the growth of a thriving economic ecosystem for Arizona’s Bioscience Industry. For more information visit .AZBio.org and .AZBio.TV About the Biodesign Institute The Biodesign Institute at ASU addresses today’s critical global challenges in healthcare, sustainability and security by developing solutions inspired from natural systems and translating those solutions into commercially viable products and clinical practices. For more information visit biodesign.asu.edu Photos available upon request.

Gilead annuncia un nuovo contratto con la fondazione Medicines Patent Pool per l'accesso ai suoi farmaci nei Paesi in via di sviluppo

MELBOURNE, Australia--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) ha annunciato oggi in occasione della 20ma edizione della Conferenza Internazionale sull AIDS tenuta a Melbourne, Australia, un nuovo contratto con la fondazione Medicines Patent Pool (MPP) per ampliare l accesso al farmaco sperimentale di Gilead tenofovir alafenamide (TAF) per il trattamento dell infezione da HIV e dell epatite B, previa l approvazione del farmaco da parte dell ente normativo statunitense competente. Ai sensi del contratto in oggetto, MPP potr`a subconcedere in licenza TAF a case farmaceutiche impegnate nella produzione di farmaci generici in India e in Cina che potranno produrre e distribuire i prodotti in 112 Paesi in via di sviluppo. “Medicines Patent Pool svolge un ruolo fondamentale per quanto concerne gli sforzi attuati per espandere l accesso alle terapie anti-HIV nei Paesi in via di sviluppo”, ha affermato Gregg H. Alton, Vicepresidente esecutivo della divisione Affari medici e aziendali presso Gilead Sciences. Buy Aygestin (Norethisterone Bp) with no prescription “Espandendo la nostra collaborazione per includervi ora TAF, ci auspichiamo di spianare la strada all introduzione rapida delle versioni generiche, qualora il farmaco venisse approvato”. Il nuovo contratto di licenza amplia il rapporto di collaborazione intrattenuto da Gilead con MPP. About Azelex (Azelaic Acid) with free prescription Nel luglio del 2011 Gilead `e divenuta la prima societ`a farmaceutica ad aderire alla fondazione MPP e oggi sei case farmaceutiche indiane sono titolari di sottolicenze concesse da MPP per i farmaci anti-HIV di Gilead. “Quale il primo partner del settore farmaceutico della fondazione Medicines Patent Pool, Gilead ha svolto un ruolo essenziale nell ampliamento dell accesso alle terapie per le persone affette da HIV nei Paesi in via di sviluppo”, ha affermato Greg Perry, Direttore esecutivo di MPP. About Aygestin (Norethindrone Acetate) with no prescription “Accogliamo con vivo entusiasmo questa espansione della nostra collaborazione e siamo ansiosi di collaborare con i nostri sottolicenziatari per offrire l accesso a versioni d alta qualit`a e a basso costo di TAF e di altri farmaci antiretrovirali di Gilead”. Gli accordi di licenza costituiscono i pilastri su cui poggiano gli sforzi attuati da Gilead allo scopo di accrescere l’accesso alle terapie sviluppate dalla societ`a nei Paesi in via di sviluppo. Buy Cyclogyl with no prescription Oltre al contratto stipulato con MPP, Gilead intrattiene rapporti di collaborazione diretta con 11 produttori di farmaci generici. Buy Pomegranate online In considerazione della concorrenza tra i suddetti produttori di farmaci generici, il prezzo minimo di una farmaco anti-HIV di Gilead `e sceso dell 80 per cento dal 2006 assestandosi su 4 dollari per paziente al mese. http://cardiobloodreview.wordpress.com Al momento 5,4 milioni di persone stanno ricevendo farmaci anti-HIV di Gilead in Paesi a reddito medio-basso tramite le iniziative della societ`a per l ampliamento dell accesso; pi`u della met`a di tutte le persone che stanno seguendo una terapia anti-HIV in questi Paesi. Il novantanove per cento di queste persone riceve delle versioni prodotte dai partner produttori di farmaci generici. La versione integrale del contratto di licenza con MPP `e rinvenibile all indirizzo .medicinespatentpool.org. Informazioni su tenofovir alafenamide Tenofovir alafenamide (TAF) `e un inibitore nucleotidico della trascrittasi inversa (NtRTI). Si tratta di un nuovo profarmaco di tenofovir. Negli studi a dosaggio variabile di Fase 1b si `e identificata una dose di TAF che `e di dieci volte inferiore a quella di Viread® (tenofovir disoproxil fumarato), il che potrebbe accrescerne l uso in popolazioni di pazienti pi`u ampie. Gilead sta conducendo attualmente delle sperimentazioni cliniche di Fase III per valutare la sicurezza e l efficacia di TAF come agente a se stante per il trattamento dell infezione da virus dell epatite B cronica (HBV). Per l infezione da HIV, Gilead sta valutando un regime monocompressa contenente TAF in combinazione con elvitegravir, cobicistat e emtricitabina (E/C/F/TAF). Questo regime monocompressa `e attualmente studiato nell ambito di un programma esaustivo di Fase III su pazienti sia na"ive al trattamento che precedentemente trattati affetti da insufficienza renale. Inoltre, si stanno conducendo altri studi di Fase III intesi a valutare dei regimi combinati a dosaggio fisso contenenti due dosi di TAF in combinazione con emtricitabina (F/TAF); si stanno anche studiando una dose ridotta di 10 mg per l uso con inibitori della proteasi potenziati e una dose di 25 mg per l uso con altre classi di farmaci anti-HIV. L approccio di Gilead all accesso alle terapie Gilead attribuisce importanza prioritaria all ampliamento dell accesso ai suoi farmaci per le persone che possono trarne giovamento, a prescindere dalla loro ubicazione geografica o dai loro mezzi economici. Le strategie per l espansione dell accesso alle terapie anti-HIV di Gilead includono diversi livelli di prezzi, collaborazione con i governi nazionali, collaborazioni con aziende operanti a livello regionale, registrazione dei prodotti, educazione medica e collaborazioni con organizzazioni senza scopo di lucro. Informazioni su Gilead Sciences Gilead Sciences `e un’azienda biofarmaceutica impegnata nella ricerca, nello sviluppo e nella commercializzazione di terapie innovative nei settori della medicina che presentano problemi ancora irrisolti. La missione dell’azienda consiste nel promuovere l’avanzamento delle cure per pazienti affetti da malattie potenzialmente letali in tutto il mondo. Gilead, la cui sede generale `e ubicata a Foster City, California, opera nel Nord America e nel Sud America, in Europa e nella regione Asia Pacifico. Dichiarazioni rilasciate a titolo di previsione Il presente comunicato stampa contiene delle dichiarazioni di previsione secondo il significato attribuito a tale espressione dalla legge statunitense Private Securities Litigation Reform Act del 1995 che comportano rischi, incertezze e altri fattori, compresa la possibilit`a che i licenziatari non riescano a produrre e distribuire delle versioni generiche dei farmaci di Gilead, che i termini del contratto di licenza vengano modificati o che TAF non venga approvato. I risultati effettivi potrebbero discostarsi in maniera sostanziale da quelli riportati nelle dichiarazioni di previsione in considerazione di tali rischi, incertezze e altri fattori. Si invitano i lettori a non fare eccessivo affidamento sulle presenti dichiarazioni di previsione. I suddetti e altri rischi sono descritti in termini particolareggiati nella relazione trimestrale di Gilead contenuta nel Modulo 10-Q riferita al trimestre conclusosi il 31 marzo 2014, che `e stata depositata presso l’ente statunitense Securities and Exchange Commission. Tutte le dichiarazioni di previsione sono basate sulle informazioni attualmente a disposizione di Gilead, la quale non si assume alcun obbligo riguardo all’aggiornamento di tali dichiarazioni. Viread `e un marchio commerciale registrato di Gilead Sciences, Inc. Per ulteriori informazioni su Gilead Sciences visitare il sito web dell’azienda all’indirizzo .gilead.com, seguire Gilead su Twitter (@GileadSciences) o chiamare l’ufficio Relazioni pubbliche di Gilead ai numeri 1-800-GILEAD-5 o 1-650-574-3000 Il testo originale del presente annuncio, redatto nella lingua di partenza, `e la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit`a del lettore e devono rinviare al testo in lingua originale, che `e l unico giuridicamente valido.

Terumo BCT er"offnet Produktionsst"atte in Vietnam

LAKEWOOD, Colorado (USA)--(BUSINESS WIRE)--Terumo BCT, weltweit f"uhrend bei Blutkomponenten, therapeutischer Apherese und Zelltechnologien, hat heute die Er"offnung seiner neuen 91.440 Quadratmeter grossen Produktionsst"atte nahe Ho Chi Minh City in Vietnam bekannt gegeben. Die 100 Millionen US-Dollar teure Produktionsst"atte dient der Expansion des weltweiten Gesch"afts von Terumo BCT. Die Produktionskapazit"at des Unternehmens wird sich Anfang 2015 erh"ohen, wenn die neue Fabrik in Betrieb genommen wird. Wichtige Fakten: Terumo BCT ist ein global t"atiger Hersteller medizinischer Ger"ate und hat seinen Hauptsitz in Lakewood im US-Bundesstaat Colorado. Weitere regionale Firmensitze unterh"alt das Unternehmen in: Br"ussel, Buenos Aires, Hongkong und Tokio Die 100 Millionen US-Dollar schwere Investition ist in den Bau einer 91.440 Quadratmeter grossen Fabrik von Terumo BCT auf einem 10 Hektar umfassenden Gel"ande in der N"ahe von Ho Chi Minh City geflossen. Wenn die Einrichtung einmal vollst"andig in Betrieb ist, wird sie eine Belegschaft von mehr als 900 neuen Mitarbeitern beherbergen. Die Er"offnung der Einrichtung in Vietnam bringt die Zahl der L"ander, in denen Produkte von Terumo BCT hergestellt werden, auf sieben: Belgien, China, Indien, Japan, Nordirland, die USA und Vietnam In Vietnam werden Blutbeutel und Verbrauchsmaterialien f"ur die automatisierte Blutentnahme produziert werden Terumo BCT verf"ugt derzeit "uber eine Belegschaft von 4.800 Mitarbeitern und ist haupts"achlich in drei Kundensegmenten in "uber 120 L"andern und Gebieten t"atig: Blutzentren, therapeutische Apherese und Blutentnahme sowie Blutverarbeitung Die Einrichtung in Vietnam ist Teil der umfassenden Strategie von Terumo BCT, die Investitionen in vorhandene Produktionsst"atten am internationalen Unternehmenssitz im US-Bundesstaat Colorado sowie in Produktionsst"atten in Nordirland und Indien vorsieht. Wichtige Kommentare: Craig Rinehardt, Executive Vice President f"ur Global Operations bei Terumo BCT „Die Fertigstellung dieser Produktionsst"atte spiegelt unseren kontinuierlichen Einsatz gegen"uber unseren Kunden auf s"amtlichen Kontinenten wider, insofern als wir globale Kapazit"aten und Produktionstechniken weiterentwickeln, die in Vietnam eingesetzt werden, um die Markteinf"uhrungszeit zu verk"urzen, und die uns bef"ahigen, Kundenbed"urfnisse besser zu erf"ullen.“ „Vom Beginn der Erdarbeiten, "uber den Bau bis zur Fertigstellung ist weniger als ein Jahr vergangen. About Zyrtec (Cetirizine) without prescription Dank der Hilfe so vieler Beteiligter haben wir diese Investition in die Realit"at umgesetzt. About Zyvox (Linezolid) with free prescription Wir sind "uber die Er"offnung der Produktionsst"atte in Vietnam begeistert und sehen sie als eine willkommene Erg"anzung unserer Fertigung am Unternehmenssitz in den USA sowie unserer Betriebe weltweit.“ Yutaro Shintaku, Pr"asident und Representative Director der Terumo Corporation „Die neue Produktionsst"atte von Terumo BCT ist das j"ungste Beispiel daf"ur, wie die Terumo Corporation in seine Kapazit"aten auf globaler Ebene investiert – die Er"offnung dieser Einrichtung ist ein aufregender neuer Schritt f"ur uns. About Voltaren (Diclofenac Sodium) without Rx Wir sind zuversichtlich, dass die neue Einrichtung Gelegenheiten mit sich bringen wird, um vom Wachstum in der Region zu profitieren, w"ahrend wir weiterhin unserem Auftrag nachgehen, durch Gesundheitsversorgung einen Beitrag zur Gesellschaft zu leisten.“ Wichtige Quellen: Vietnam 2014 Facility Photos Vietnam 2013 Groundbreaking Terumo BCT Colorado Investment Terumo BCT Northern Ireland Investment "Uber Terumo BCT: Terumo BCT, weltweit f"uhrend bei Blutkomponenten, therapeutischer Apherese und Zelltechnologien, ist das einzige Unternehmen, das die einmalige Kombination von apheretischer Blutentnahme, manueller und automatisierter Blutverarbeitung und Reduzierung von Pathogenen aufweist. Clopra without prescription Wir sind der Meinung, dass mit Blutkonserven k"unftig noch mehr f"ur die Patienten getan werden kann als heute. Buy MSM online Diese Zuversicht regt unseren Innovationsgeist an und st"arkt unsere Zusammenarbeit mit Kunden. Die Ausgangssprache, in der der Originaltext ver"offentlicht wird, ist die offizielle und autorisierte Version. http://cardiobloodreview.wordpress.com "Ubersetzungen werden zur besseren Verst"andigung mitgeliefert. Nur die Sprachversion, die im Original ver"offentlicht wurde, ist rechtsg"ultig. Gleichen Sie deshalb "Ubersetzungen mit der originalen Sprachversion der Ver"offentlichung ab.

InSite Vision Announces the Issuance of Broad U.S. Patent Covering Bromfenac Formulations in DuraSite®

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. Buy Diamox (Acetazolamide) with no prescription The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite’s bromfenac product candidates, including BromSite™ (bromfenac 0.075% ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Diflucan (Fluconazole) without Rx Additional bromfenac-containing products in InSite’s pipeline covered under this patent include: ISV-101 (bromfenac 0.01%-0.04% ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as the combination of bromfenac and dexamethasone containing products such as BromDex™ (ISV-504). Detrol (Tolterodine) Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029. InSite has successfully completed two Phase 3 clinical trials of BromSite and plans to file a New Drug Application (NDA) with the U.S. Buy Desal with free Rx Food and Drug Administration (FDA) in the second half of 2014. Buy Snacks online BromSite demonstrated statistically significant improvements versus vehicle across the primary and secondary endpoints of alleviating ocular inflammation, post-surgical reduction in pain and reduction in inflammatory flare in InSite’s pivotal clinical studies. http://cardiobloodreview.wordpress.com InSite Vision recently announced that the Swedish Medical Products Agency (MPA) determined that the existing Phase 3 clinical data for BromSite for the prevention of pain and inflammation in ocular surgery was likely sufficient to support the filing of a Marketing Authorization Application (MAA) with the MPA. InSite plans to pursue European regulatory approvals of BromSite following the submission of its U.S. NDA. About InSite Vision InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn Inc.; and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite Vision is also advancing AzaSite Plus™, a novel ophthalmic therapeutics through Phase 3 clinical studies for the treatment of eye infections, and is preparing two new drug applications (NDA) for the commercial approval by the U.S. Food & Drug Administration (FDA): BromSite™ for the treatment of inflammation and prevention of pain associated with cataract surgery and DexaSite™ for the treatment of blepharitis. For further information on InSite Vision, please visit .insitevision.com. Forward-looking Statements This news release contains certain statements of a forward looking nature relating to future events, including the filing of an NDA and MAA for BromSite in the United States and the European Union, respectively; the Company’s current plans to pursue regulatory approval for its product candidates; and the potential indications for the Company’s pipeline drug candidates. Such statements entail a number of risks and uncertainties, including but not limited to: the Company’s ability to obtain substantial additional funding given that its current cash is currently projected to run out in September 2014, that the scope of patent protection for bromfenac may be less than anticipated, that the patent could subsequently be challenged or that others may allege infringement of their patents or technologies, the ability of the Company to file and receive approval for its BromSite NDA and MAA and the timing thereof; the ability of the Company to enter into corporate collaborations for its product candidates; the Company’s ability to expand its product platform; the Company’s ability to compete effectively, either alone or through its partners, with other companies offering competing products or treatments; the Company’s ability to maintain and develop additional collaborations and commercial agreements with corporate partners, its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA. Reference is made to the discussion of these and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward-looking statements or projections are based on the limited information currently available to the Company, which is subject to change. Although any such forward-looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not unduly rely on such statements or information nor assume that the information provided in this release is still valid at any later date. AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.AzaSite Plus™, BromSite™, DexaSite™ and BromDex™ are trademarks of InSite Vision Incorporated.BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.

BioRestorative Therapies Issues Letter to Stockholders

JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has issued a letter to stockholders, the text of which is below. July 14, 2014 To Our Stockholders: I am very pleased to present the exciting progress BioRestorative Therapies, Inc. has made since August 2013, when I last shared an update letter with our stockholders. During the past year, we have moved closer to our goal of filing an Investigational New Drug/ Investigational Device Exemption (IND/IDE) with the U.S. About Zyrtec (Cetirizine) without prescription Food and Drug Administration (FDA) for our brtxDISC™ (Disc Implanted Stem Cells) Program, to begin a pivotal study in patients with bulging and protruding lumbar discs who have failed non-invasive procedures and face the prospect of surgery. About Zyvox (Linezolid) with free prescription The treatment involves culturing a patient’s own stem cells and then delivering them via our proprietary medical device to the damaged region of the disc in an outpatient procedure. We have also made a great deal of progress in advancing our ThermoStem® Program, an investigational treatment using brown fat stem cells for metabolic disorders including diabetes and obesity. About Voltaren (Diclofenac Sodium) without Rx Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. As a recap, below are some of our accomplishments and activities from the past year. Business Development/Partnering Activities During the first half of this year we were thrilled that two pharmaceutical companies recognized our cellular biology programs, which culminated in our signing agreements with each of them. Clopra without prescription We believe that planned collaborative work will help serve to advance the body of knowledge of our technology with the ultimate goal of developing clinical therapies. In March 2014 we announced a Research and Development Agreement with a Japanese global pharmaceutical company, Rohto Pharmaceutical Company, Ltd., under which we will provide stem cell research and development services. Buy MSM online Rohto has approximately $1.3 billion in annual sales and develops new technology for the medical and cosmetics markets. Also in March 2014 we entered into a two-year collaborative Research Agreement with Pfizer Inc. http://cardiobloodreview.wordpress.com to study human brown adipose (fat) tissue and cell lines. Under the terms of the agreement, we and Pfizer are jointly conducting a study titled “Development and Validation of a Human Brown Adipose Cell Model,” which will seek to further characterize the identity and metabolic function of these cell lines. We have accumulated a large collection of human brown adipose tissue samples, preadipocyte cell lines and immortalized cell lines for use in potentially developing a cell therapy product. Clinical Trial Preparation In the latter half of 2013, we received approval from the Western Institutional Review Board to complete a retrospective safety study on selected subjects previously treated by our brtxDISC™ bulging and protruding disc procedure at the Centeno-Schultz Clinic in Broomfield, Colorado, near Denver. The study, entitled “Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc,” is nearing completion and we expect to report results by the end of the year. The objective was to determine the safety of subjects who received autologous stem cell transplants into their disc, using follow-up MRI results and Quality of Life Questionnaires. We intend to use the safety results of the study in our FDA filing. To assist us in the preparation of the medical delivery device requirements for advancing through the regulatory process, we engaged the consultancy firm Phil Triolo and Associates, LC during the second half of 2013. Publications and Scientific Presentations Our Chief Scientist and Vice President of Research and Development, Francisco Silva, presented preclinical data from our ThermoStem® brown fat stem cell Program in November 2013 at the 11th Annual Meeting of the International Federation for Adipose Therapeutics and Science (iFATS) in New York City. In February, our preclinical brown fat study was published in the peer-reviewed journal Stem Cells. A photograph of our brown fat cell scaffold appeared prominently on the cover. Our research demonstrated that functional brown adipose derived stem cells (BADSCs) produced improvements in mice with diet-induced metabolic disorder. The results of the study showed for the first time that a multipotent stem cell population exists in human adult adipose deposits, and that this population can be differentiated into metabolically functional brown adipocytes. Brown adipocytes are key cells that are involved in energy homeostasis and metabolism. In humans, loss of brown adipose related activity may account for the lower metabolism often associated with diabetes and obesity. Publication in this journal was an important validation of the scientific rigor of our work. Scientific Advisors and Board Members During the past 12 months we strengthened our management team, Board of Directors and Scientific Advisory Board. Gregory Lutz, M.D. was named Chief Medical Advisor for Spine Medicine for our brtxDISC™ Program. Dr. Lutz is leading the efforts to design our clinical trial protocol, identify trial sites and assist in the selection of a contract research organization (CRO) to conduct the studies. Dr. Lutz also will interact on our behalf with the FDA and the investment community. Dr. Lutz is Associate Professor of Clinical Rehabilitation Medicine at Weill Medical College of Cornell University in New York City, and an attending physician at the Hospital for Special Surgery. In April 2014, we were pleased to add Wayne Olan, M.D. to our Scientific Advisory Board, to assist with the clinical development of our disc program. Dr. Olan, a board-certified interventional neuroradiologist, is the director of endovascular and minimally invasive image guided neurosurgery at the George Washington University Medical Center in Washington, D.C., and is an associate professor at The George Washington University School of Medicine & Health Sciences. Dr. Olan also serves as a consulting physician to the National Institutes of Health. In recent weeks we made two outstanding additions to our Board of Directors: The Honorable Paul Jude Tonna, a highly regarded community leader and an accomplished businessman with an extensive history of public service, will chair the Compensation Committee and is serving on the Audit and Nominating Committees of the Board. He was a long-time Suffolk County Legislator and is currently Executive Director and a member of the Board of Advisors for The Energeia Partnership at Molloy College, a leadership academy based in Rockville Centre, N.Y. dedicated to identifying and addressing the serious, complex and multi-dimensional issues challenging the Long Island region. Joseph B. Swiader will chair the Nominating Committee and serve on the Compensation Committee of the Board. He has extensive experience in both the financial and biotechnology sectors. He is currently managing partner of Wet Earth Partners LLC, which he founded in 2002. Wet Earth Partners invests in a range of ventures that include biotechnology, medical technology and consumer products. Corporate Activities We are engaged in negotiations to move our corporate headquarters and operations to Long Island, N.Y. from Jupiter, Fla. We have identified a location we expect will enable us to grow over the coming years and have preliminarily been approved for certain tax abatement benefits from New York’s Suffolk County Industrial Development Agency. We have been active in reaching the investment community during the past 12 months, presenting at the LD Micro Conference in Los Angeles in December 2013 and at the Marcum MicroCap Conference in New York in May 2014. We continue to work to raise our profile among the investment community. LD Micro is a by-invitation only newsletter firm that focuses on finding undervalued micro-cap companies. Marcum hosted nearly 100 publicly traded companies with market capitalizations under $500 million, and attracted more than 1,000 people including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace. Looking Ahead We have a number of exciting initiatives in the coming months: We expect to announce results from our retrospective study of the brtxDISC™ Program by the end of the year and, shortly thereafter, we expect to hold our first meeting with the FDA, as we plan our clinical trial. With regard to our ThermoStem® Program, we are continuing our tissue procurement efforts, building our library of brown adipose (fat) tissue and stem cell lines. As a result of our collaboration with Pfizer, we are well positioned to accelerate our research and advance the program toward a clinical trial. As we continue to make plans to relocate our laboratory and corporate headquarters, we expect to hire additional laboratory and scientific staff to accelerate our research and development efforts, as well as additional corporate personnel to support our operations. We have been working to shore up our financial position, and since my last stockholder letter we have raised approximately $3 million through equity and debt issuances, including a warrant exercise program. We continue to seek additional funding to advance our programs. In summary, we are executing on our plans and are very excited about the potential of our programs to make a sizable impact on the health of patients, while working to create value for our stockholders. I am grateful for the continued support of our employees, strategic partners and stockholders. Sincerely, Mark Weinreb, Chief Executive Officer BioRestorative Therapies, Inc. .biorestorative.com This letter contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this letter are made as of the date hereof and we undertake no obligation to update such statements. About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including: brtxDISC™ (Disc Implanted Stem Cells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient’s own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure. ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to crease the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties. The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at .stempearls.com.

Great Success for the First Edition of “French Life Sciences Days”

PARIS--(BUSINESS WIRE)--France Biotech, (.france-biotech.org), an association of entrepreneurs in the life sciences industry, today announced the high level of interest in the first edition of “French Life Sciences Days” on June 25th and 26th in New York and is pleased to announce the event renewal next year on June 17th and 18th in New York. This brand new initiative allowed 19 Life Sciences companies, recently listed or more mature, with a market capitalization from Euro 25 to 477 million, developing Biotech and Medtech breakthrough technologies with advanced clinical results or sales. Their CEOs have displayed their business plans to 50 American non-specialized and specialized financial investors. Our firms’ investment opportunities have attracted prestigious names of Finance from Boston, New York and Philadelphia. These investors showed a tremendous interest in the 19 innovative companies during 70 one-to-one meetings (about 4 meetings per company).This first edition has also been broadly covered in French and American media (Forbes, The Wall Street Journal: on.wsj.com/1wBk3UW, Reuters, Les Echos, La Tribune, and a specific coverage from BFM Business). “The Life Sciences Days are a major element in promoting and reinforcing the whole innovative SMEs funding scene, from startup to more mature companies. Buy Vaseretic (Enalapril-Hydrochlorothiazide) without Rx Our goal has been achieved: French innovation in the healthcare field has been recognized in the United States and the investors are convinced that world future champions are among us! The French financial players confirm Euronext’s leading position. Vasotec (Enalapril) without prescription This event’s success calls for further ones and we will renew this event on June 17th and 18th 2015 in New York and already plan the same initiative in Asia. About Thorazine (Chlorpromazine) with no prescription I particularly thank our sponsors, Bryan Garnier & Co, Soci et e G en erale, Invest Securities, Deloitte, Mazars and NewCap who have been key to this success!”, Pierre-Olivier Goineau, the president of France Biotech, said. About the “French Life Sciences Days”This new initiative by France Biotech aims at fostering and boosting the connections between French public companies and investors worldwide in an effort to facilitate exchanges and demonstrate the solidity of our own financial community. Buy Citadep with no prescription The first edition will be held in New York. Buy Maitake Mushroom online This “French Life Sciences Days” initiative brings together key Parisian players (banks, brokers, analysts, auditors, lawyers and communication agencies) to form a sponsorship committee that will support entrepreneurs in the life sciences. http://cardiobloodreview.wordpress.com During this occasion, the French biotech and medtech companies listed on the NYSE Euronext exchange will introduce themselves to international investors. About France BiotechFrance Biotech brings together the main French life science companies and their expert partners. Its mission is to support the development of the French life sciences by advocating for a favorable regulatory and fiscal environment. In 2004, France Biotech successfully lobbied the French government to create a special fiscal status for innovative start-ups and continues to act as an advocate for the French innovative sector. The organization is currently chaired by Pierre-Olivier Goineau, Co-Founder and CEO of ERYTECH Pharma. France Biotech has over 150 members and its board of directors is composed of 20 entrepreneurs in the life sciences.

Baxter Appoints John Orloff, M.D., Vice President of BioScience R&D

Baxter Appoints John Orloff, M.D., Vice President of BioScience R&D

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the appointment of John Orloff, M.D., as vice president and global head of research and development for Baxter BioScience, effective immediately. Dr. Orloff joins Baxter from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Buy Precose (Acarbose) with no Rx Dr. About Premarin (Conjugated Estrogens) with free Rx Orloff will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model and pursuing additional innovative opportunities for the business. As we work toward becoming an independent global biopharmaceutical company, our priorities are to drive innovation by advancing our rich, late-stage development pipeline, expanding our expertise in immunology, hematology, and other core technologies and optimizing our R&D productivity, said Ludwig Hantson, Ph.D., president of Baxter BioScience. Parafon (Chlorzoxazone) with no prescription John brings significant scientific and leadership expertise, including preclinical research, clinical development, and medical and regulatory affairs. Cefadroxil with no prescription He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organization. Buy Horsetail online Prior to his tenure at Merck Serono, Dr. http://cardiobloodreview.wordpress.com Orloff spent approximately 10 years at Novartis, where he served in roles of increasing responsibility including chief medical officer for global development. Earlier in his career, Dr. Orloff supported clinical development at Merck Research Labs and was previously a faculty member at the Yale University School of Medicine. Dr. Orloff’s expertise in bone biology contributed to marketing approvals for treatments for a range of bone disorders, and he has led programs across a diverse range of therapeutic areas, including immunology, neurology and oncology. Dr. Orloff received an undergraduate degree in chemistry from Dartmouth College and earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine. About Baxter International Inc. Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies, today announced the appointment of Richard Murray, Ph.D., to chief executive officer. Dr. Murray brings to Jounce more than two decades of experience building biologics R&D capabilities and moving exciting science through development for both startup biotechnology and large pharmaceutical companies. Dr. Buy Naprosyn (Naproxen) with no prescription Murray succeeds interim CEO Cary Pfeffer, M.D., a partner at Third Rock Ventures, who will assume the position of chairman of Jounce’s board of directors. Dr. Buy Neggram (Nalidixic Acid) without Rx Murray joins Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research, and was a member of the Merck Research Laboratories (MRL) leadership team. Micardis Hct (Telmisartan, Hydrochlorothiazide) with free Rx There, he was responsible for the advancement of protein therapeutics and vaccines across a breadth of therapeutic areas, from discovery through development and manufacturing, including Merck’s immunotherapy programs. “Rich has a strong entrepreneurial spirit coupled with deep experience directing basic and translational research of biologic therapeutics,” said Dr. Canesten with free Rx Pfeffer. Buy Guggul online “More specifically, his leadership was instrumental to the successful advancement of Merck’s anti-PD-1 program and recent BLA filing. http://cholesterolreviews.wordpress.com Rich has the strategic skillset and insight to execute on our long-term vision and propel Jounce into the drug development stage.” “This is a seminal time in the field of cancer immunotherapy and I am thrilled to be joining Jounce during this exciting period,” said Dr. Murray. “The company’s early investment in translational science, including strategic alliances with several major academic centers, along with the active engagement of Jounce’s founders, creates a unique opportunity to validate and advance the next generation of cancer immunotherapy targets and drugs. I look forward to working with the board, founders and the rest of the Jounce team to rapidly advance our exciting preclinical pipeline and bring forward new cancer treatments that can significantly improve patients’ long-term survival.” Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. He was the executive vice president and chief scientific officer at PDL BioPharma, and previously, he was co-founder and vice president of research at EOS Biotechnology, acquired in 2003 by Protein Design Labs. Prior to these executive level roles, he spent more than 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma and now represents the main site for Merck’s Biologics discovery efforts. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst. About Jounce Therapeutics Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit .jouncetx.com.

Cadwalader Advising Salix Pharmaceuticals in its Combination with Cosmo Technologies to Form Salix Pharmaceuticals, plc

. About Lamictal Dispersible (Lamotrigine) with free Rx NEW YORK--(BUSINESS WIRE)--Cadwalader is pleased to be advising Salix Pharmaceuticals, Ltd. Buy Buspar with free Rx in its announced combination with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A., pursuant to which Salix will become a wholly-owned subsidiary of Irish incorporated Cosmo Technologies, which will change its name to Salix Pharmaceuticals, plc. Under the terms of the agreement, Salix Pharmaceuticals, plc will own Cosmo’s U.S. Buy GABA online patents for rifamycin MMX®, methylene blue MMX® and Uceris®, and have specified rights of negotiation with respect to all products Cosmo or its affiliates seek to develop or commercialize in the U.S. http://cholesterolreviews.wordpress.com In addition, Salix Pharmaceuticals, plc will acquire Cosmo’s patents for rifamycin MMX in Canada, specified Latin American countries, India, China, Japan and the rest of the Far East, excluding Australia and New Zealand, and Cosmo’s patents for Uceris in Japan. The Cadwalader team is led by partners Christopher Cox (Corporate), Geoffrey Levin (Corporate), Ira Schacter (Corporate), Linda Swartz (Tax) and James Woolery (Corporate) and special counsel Aly El Hamamsy (Corporate) in New York, and partner Adam Blakemore (Tax) and special counsel Paul Dunbar (Corporate) in London. About Cadwalader, Wickersham & Taft LLP Cadwalader, Wickersham & Taft LLP, established in 1792, serves a diverse client base, including many of the world s leading financial institutions and corporations in more than 50 countries. About Levitra (Vardenafil) With offices in New York, London, Charlotte, Washington, Houston, Beijing, Hong Kong and Brussels, Cadwalader offers legal expertise in antitrust, banking, corporate finance, corporate governance, energy, environmental, executive compensation, financial restructuring, health care, intellectual property, litigation, mergers and acquisitions, private equity, private wealth, real estate, regulation, securitization, structured finance, tax and white collar defense. About Lexapro (Escitalopram) with free Rx For more information, visit .cadwalader.com.

Celanese Presents Predictive Modeling from EVA Polymers at Controlled Release Society’s 41st Annual Meeting & Expo

DALLAS--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global technology and specialty materials company and a global leader in ethylene vinyl acetate (EVA) polymers, invites attendees of the 41st Annual Meeting & Exposition of the Controlled Release Society (CRS) in Chicago, Ill., to attend a poster session entitled “Predictive Modeling and Validation of Tamoxifen Release from EVA Copolymers.” “EVA polymers are well-known as a controlled release drug delivery platform for use with many challenging drug molecules,” said Dr. Bin Zhang, Celanese senior chemist. “The Celanese VitalDose® brand of EVA copolymers offers full biocompatibility and is well suited to the design of complex release profiles and dosage forms using low temperature melt extrusion technology. This study further demonstrates the versatility of VitalDose® EVA, offering predictively-modeled dosage of the key oncology drug Tamoxifen.” As a unique and established controlled release excipient, EVA was evaluated in the study with selected active pharmaceutical ingredients (APIs). About Diovan Hct (Valsartan-Hydrochlorothiazide) without Rx The API solubility and release profiles were studied using Hansen Solubility Parameter calculations and experimental in vitro elution. Diprolene (Betamethasone) with no prescription The paper demonstrates a method that can be used for initial formulation design for controlled drug delivery from EVA copolymers. The poster session will be presented Sunday, July 13, 2014, with Dr. Buy Diflucan (Fluconazole) with no prescription Zhang in attendance from 3:00-4:00 p.m. Becaplermin with free prescription (Poster #295). Buy Diuretics online The poster will be available at general poster sessions through July 15. A whitepaper will also be available at Celanese booth #215 at the CRS exposition where marketing and technical experts will be available for questions. http://mdreview.wordpress.com The abstract and poster will be available for download at .celanese.com. About Celanese Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. With sales almost equally divided between North America, Europe and Asia, the company uses the full breadth of its global chemistry, technology and business expertise to create value for customers and the corporation. Celanese partners with customers to solve their most critical needs while making a positive impact on its communities and the world. Based in Dallas, Texas, Celanese employs approximately 7,400 employees worldwide and had 2013 net sales of $6.5 billion. For more information about Celanese Corporation and its product offerings, visit .celanese.com or our blog at .celaneseblog.com. All trademarks indicated above are owned by Celanese International Corporation or its affiliates. Forward-Looking Statements This release may contain “forward-looking statements,” which include information concerning the company s plans, products, objectives, goals, strategies, future revenues or performance, capital expenditures, and other information that is not historical information. When used in this release, the words “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” “may,” “can,” “could,” “would,” “might,” “will” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or its customers will realize these benefits or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: changes in general economic, business, political and regulatory conditions; changes in the price and availability of raw materials; the introduction of competing products by other companies; market acceptance of our products; changes in the degree of intellectual property and other legal protection afforded to our products and processes; the impact of technological developments and competition; adoption of new or different industry or regulatory standards; unanticipated operational or commercial difficulties, including failure of facilities or processes or products to be designed or constructed, or to operate, in accordance with specifications or expectations; the ability to achieve and maintain plant utilization; ability of third parties, including our commercial partners, suppliers or others, to comply with their commitments to us; increased costs under existing or future environmental regulations, including those relating to climate change; potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate; and various other factors discussed from time to time in the company s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Research and Markets Global and US Hypertension Pipeline Report 2014-2017

Research and Markets Global and US Hypertension Pipeline Report 2014-2017

. DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/47rb45/hypertension) has announced the addition of the "Hypertension Pipeline Highlights - 2014 Update" report to their offering. The latest report Hypertension Pipeline Highlights - 2014 Update, provides most up-to-date information on key pipeline molecules in the global Hypertension market. It covers emerging therapies for Hypertension in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals. Clinical Trial Stages: The report provides Hypertension pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage. Drug Mechanism Classes: The report provides Hypertension pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds. Company: The report provides Hypertension pipeline molecules by the Originator Company. Short-term Launch Highlights: Find out which Hypertension pipeline products will be launched in the US and Ex-US till 2017. Summary: Hypertension phase 3 clinical trial pipeline molecules Hypertension phase 2 clinical trial pipeline molecules Hypertension phase 1 clinical trial pipeline molecules Hypertension preclinical research pipeline molecules Hypertension discovery stage pipeline molecules Hypertension pipeline molecules short-term launch highlights For more information visit .researchandmarkets.com/research/47rb45/hypertension

Alnylam to Host “RNAi Roundtable” Webcast Series

Alnylam to Host “RNAi Roundtable” Webcast Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online “RNAi Roundtables” during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the “Alnylam 5x15” programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company’s website, .alnylam.com. About Cleocin (Clindamycin) without prescription An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event. The RNAi Roundtable topics scheduled to date include: Patisiran and ALN-TTRsc for the treatment of Transthyretin-Mediated Amyloidosis (ATTR) Tuesday, July 15: 12:30 – 2:00 p.m. Clomid (Clomiphene) with no prescription ET Jared Gollob, M.D., Vice President, Clinical Research Moderator: John Maraganore, Ph.D., Chief Executive Officer Guest Speaker: Philip N. About Cipro (Ciprofloxacin) without Rx Hawkins, M.B., B.S., Ph.D., FRCP, Professor of Medicine, National Amyloidosis Centre, University College London Medical School Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates Tuesday, July 22: 11:00 a.m. Buy Augmentin with no prescription – 12:00 p.m. Buy Cough online ET Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection Tuesday, July 29: 9:30 – 10:30 a.m. http://mdreview.wordpress.com ET Laura Sepp-Lorenzino, Ph.D., Vice President, Entrepreneur-in-Residence Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer Guest Speaker: Graham Foster, Ph.D., FRCP, Professor of Hepatology at Queen Mary University of London ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders Thursday, August 7: 9:30 – 10:30 a.m. ET Akin Akinc, Ph.D., Director, Research Moderator: John Maraganore, Ph.D., Chief Executive Officer Guest Speaker: Flora Peyvandi, M.D., Ph.D., Head of the Department of Internal Medicine and Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, University of Milan. ALN-CC5 for the treatment of Complement-Mediated Diseases Wednesday, August 13: 9:30 – 10:30 a.m. ET Benny Sorensen, M.D., Ph.D., Medical Director, Clinical Development Moderator: Barry Greene, President and Chief Operating Officer Guest Speaker: Anita Hill, MBChB (Hons), MRCP, FRCPath, Ph.D., Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK, and Honorary Senior Lecturer at the University of Leeds Alnylam plans to schedule additional RNAi Roundtables covering other pipeline programs to take place in the coming weeks, including ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCSsc for the treatment of hypercholesterolemia; and ALN-AAT for the treatment of AAT deficiency-associated liver disease. The topics, dates, and times of these events will be posted on the Capella section of the company’s website, .alnylam.com/capella. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company’s “Alnylam 5x15TM” product strategy. Alnylam’s genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an RNAi therapeutic targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia; and other programs yet to be disclosed. As part of its “Alnylam 5x15” strategy, as updated in early 2014, the company expects to have six to seven genetic medicine product candidates in clinical development - including at least two programs in Phase 3 and five to six programs with human proof of concept - by the end of 2015. Alnylam is also developing ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection. The company’s demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna Therapeutics, a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit .alnylam.com.

Research and Markets PharmaPoint Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

. Activelle with no Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/qfvnhr/pharmapoint) has announced the addition of the "PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Buy Apple Cider Vinegar online Historically, the treatment paradigm has centered around chemotherapy. http://mdreview.wordpress.com However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Scope Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. Annualized NSCLC therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NSCLC therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. About Avelox (Moxifloxacin) without prescription The most promising 13 candidates in Phase III development are profiled. Analysis of the current and future market competition in the global NSCLC market. About Aventyl (Nortriptyline) with no Rx Insightful review of the key industry drivers, restraints and challenges. Avelox (Moxifloxacin) without prescription Each trend is independently researched to provide qualitative analysis of its implications. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned: Roche/Genentech Pfizer Bristol-Myers Squibb Eli Lilly Boehringer Ingelheim Novartis For more information visit .researchandmarkets.com/research/qfvnhr/pharmapoint

Research and Markets Italy Crohn's Disease Market Highlights - 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/6qbkkg/italy_crohns) has announced the addition of the "Italy Crohn s Disease Market Highlights - 2014" report to their offering. The latest research, Italy Crohn s Disease Market Highlights - 2014 , provides Italy crohn s disease market analysis, competitive landscape, and crohn s disease drug sales forecast in Italy. The research includes Italy crohn s disease market size estimates for 2013, market share forecast for six years to 2019, crohn s disease drugs market share, crohn s disease drugs sales estimates, crohn s disease drugs sales forecast, and crohn s disease late stage pipeline products. This research helps executives track competitor drugs sales and market share in Italy crohn s disease market. It supports decision making in R&D to long term marketing strategies. The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the Italy crohn s disease market. Highlights of the Research: Marketed Crohn s Disease Drugs in Italy Italy Crohn s Disease Market Analysis Crohn s Disease Drugs Sales Analysis in Italy Competitive Landscape in Italy Crohn s Disease market Crohn s Disease Late Stage Pipeline Italy Crohn s Disease Market Forecast Crohn s Disease Drugs Sales Forecast in Italy Future Competitive Landscape Key Topics Covered: 1. Crohn s Disease - Disease Definition 2. About Acticin (Permethrin) without prescription Marketed Crohn s Disease Drugs in Italy 3. About Actigall (Ursodiol (Ursodeoxycholic)) Italy Crohn s Disease Market Analysis 3a. Actonel (Residronate) with no prescription Italy Crohn s Disease Market Size 3b. Buy 515-Pill without Rx Drugs Sales in Italy Crohn s Disease Market 4. Buy Acne Treatment online Competitive Landscape in Italy Crohn s Disease Market 4a. http://mdreview.wordpress.com Drugs Market Share in Italy Crohn s Disease Market 4b. Generics Market Share in Italy Crohn s Disease Market 4c. Crohn s Disease Phase 3 Clinical Trial Pipeline Molecules 5. Italy Crohn s Disease Market - Future Market Outlook 5a. Italy Crohn s Disease Market Size Forecast 5b. Drug Sales Forecast in Italy Crohn s Disease Market 5c. Drugs Market Share in Italy Crohn s Disease Market For more information visit .researchandmarkets.com/research/6qbkkg/italy_crohns

AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies with RSV Antibody

AMSTERDAM--(BUSINESS WIRE)--AIMM Therapeutics, a leading human therapeutic antibody company, today announced that its partner MedImmune, LLC, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children. MEDI8897 originated from AIMM’s D25 antibody. Under the terms of their partnering agreement, AIMM will receive a non-disclosed milestone payment from MedImmune. D25 was developed from immortalized B cells of an individual exposed to RSV utilizing AIMM’s proprietary antibody technology platform. Preclinical studies have shown that D25 neutralizes RSV with high efficiency by recognizing a unique epitope on the prefusion structure of the F protein expressed on the virus coat. “MedImmune is the world leader in RSV infection drug development so the validation associated with the initiation of clinical studies with MEDI8897 is very pleasing to see. Buy Actigall (Ursodiol (Ursodeoxycholic)) with free Rx This milestone is further confirmation of AIMM’s unique capabilities to discover exceptional human antibodies, with high therapeutic potency, against biological targets that normally are difficult to address,” said Dr. Actonel (Residronate) without Rx Jan de Vries, AIMM’s CEO. MedImmune’s Head of Research Dr. Acular (Ketorolac, Tromethamine) with no prescription Yong-Jun Liu added: “We are excited that our partnership with AIMM Therapeutics resulted in the development of a powerful RSV antibody aimed at preventing the high morbidity and mortality of RSV infections in young children at risk.” About AIMM Therapeutics AIMM Therapeutics (AIMM) is a leading antibody company that based on its synergistic, state-of-the-art antibody technology platform develops high affinity human monoclonal antibodies directly from immortalized and selected B cells of individuals who produce antibodies with high therapeutic value and of a variety of non-human species, including rabbits. Buy 6-MP pill with no prescription AIMM antibodies can be further affinity matured in a proprietary process that does not require molecular engineering. Buy Adrenal Gland online AIMM has a broad product pipeline targeted at various cancers and chronic infections. http://medicalquestionanswers.wordpress.com AIMM has two antibodies in clinical trials and has partnered with companies such as MedImmune/ AstraZeneca, Genentech/Roche, Johnson & Johnson and Cosmo Pharmaceuticals. For more information: .aimmtherapeutics.com.

Provectus Biopharmaceuticals, Inc.'s Common Shares to Begin Trading on NYSE MKT

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. Buy Female Viagra (Sildenafil Citrate) with no Rx The company’s ticker symbol will remain “PVCT” but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.

“Provectus will join other pharmaceutical companies that benefit from NYSE’s trusted and reliable platform to raise capital.”

Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is a huge milestone for Provectus Biopharmaceuticals, and I take a great deal of personal satisfaction from this news. Minipress (Prazosin) with no Rx I believe that this will enhance our shareholder value as well as broaden our shareholder base and heighten our corporate profile in the capital markets.”
NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE’s advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. About Desyrel (Trazodone) In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.
“We welcome Provectus to the NYSE community and look forward to a strong partnership with the Company and its shareholders,” said Scott Cutler, Executive Vice President and Head of Global Listings at NYSE Euronext. Acitrin without prescription “Provectus will join other pharmaceutical companies that benefit from NYSE’s trusted and reliable platform to raise capital.”
About IntercontinentalExchange Group, Inc.
IntercontinentalExchange Group, Inc. (NYSE:ICE) is the leading network of regulated exchanges and clearing houses for financial and commodity markets. Buy Vitamins online ICE delivers transparent, reliable and accessible data, technology and risk management services to markets around the world through its portfolio of exchanges, including the New York Stock Exchange, NYSE MKT, ICE Futures, Liffe and Euronext.
Trademarks of ICE and/or its affiliates include IntercontinentalExchange, ICE, ICE block design, NYSE Euronext, NYSE, New York Stock Exchange, LIFFE and Euronext. Information regarding additional trademarks and intellectual property rights of IntercontinentalExchange Group, Inc. and/or its affiliates is located at http://www.fda-approved-rx.biz and http://www.drugsrxguide.biz.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Asthma Medications Customer Review Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry. For additional information about Provectus please visit the Company's website at http://www.allwebrx.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.